Status:
COMPLETED
Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States)
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Osteoarthritis, Knee
Eligibility:
All Genders
40+ years
Phase:
PHASE4
Brief Summary
To compare the efficacy and safety of celecoxib versus ibuprofen in subjects with osteoarthritis (OA) of the knee.
Eligibility Criteria
Inclusion
- Aged \>= 40 years old
- Diagnosed with OA of the knee according to the American College of Rheumatology and OA in flare state at baseline visit
- Functional capacity class of I-III
Exclusion
- Inflammatory arthritis or gout or pseudo-gout with acute flare within the past 2 years (subjects with fibrositis or fibromyalgia will not be excluded)
- Acute joint trauma at index joint within the past 3 months with active symptoms
- Score of \>=20 on PHQ-9 or score of \>=1 on PHQ-9 item i
- Use of mobility assisting device for \<6 weeks or use of walker
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2003
Estimated Enrollment :
393 Patients enrolled
Trial Details
Trial ID
NCT00620867
Start Date
October 1 2002
End Date
March 1 2003
Last Update
February 21 2021
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Anniston, Alabama, United States, 36207
2
Pfizer Investigational Site
Phoenix, Arizona, United States, 85051
3
Pfizer Investigational Site
Anaheim, California, United States, 92804
4
Pfizer Investigational Site
Long Beach, California, United States, 90806